AZD8186 First Time In Patient Ascending Dose Study
Status:
Completed
Trial end date:
2020-02-07
Target enrollment:
Participant gender:
Summary
This is a phase I, open-label, multicentre study of AZD8186 administered orally in patients
with advanced castrate-resistant prostate cancer (CRPC), squamous non-small cell lung cancer
(sqNSCLC), triple negative breast cancer (TNBC) and known PTEN-deficient/mutated or PIK3CB
mutated/amplified advanced solid malignancies as monotherapy and in combination with
abiraterone acetate or AZD2014.